Bulletin
Investor Alert

London Markets Open in:

Bio-Techne Corp.

NAS: TECH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 11, 2021, 4:00 p.m.

/zigman2/quotes/203973516/composite

$

415.54

Change

0.00 0.00%

Volume

Volume 1,429

Quotes are delayed by 20 min

/zigman2/quotes/203973516/composite

Previous close

$ 408.23

$ 415.54

Change

+7.31 +1.79%

Day low

Day high

$394.88

$416.14

Open

52 week low

52 week high

$228.67

$444.83

Open

John L. Higgins

Currently, John L. Higgins occupies the position of Chief Executive Officer & Director at Ligand Pharmaceuticals, Inc. and Chief Executive Officer of Metabasis Therapeutics, Inc. (a subsidiary of Ligand Pharmaceuticals, Inc.). He is also on the board of Bio-Techne Corp. and Pfenex, Inc.

In the past John L. Higgins held the position of Chairman of CoMentis, Inc., CFO & EVP-Administration & Corporate Development at Connetics Corp. and Member-Healthcare Banking Team at Dillon, Read & Co., Inc.

He received an undergraduate degree from Colgate University.

Transactions

Date Shares Transaction Value
11/06/2020 3,100   Disposition at $301.06 per share. 933,286
11/06/2020 450   Disposition at $299.84 per share. 134,928
11/06/2020 1,450   Disposition at $298.98 per share. 433,521
11/06/2020 5,000   Derivative/Non-derivative trans. at $70.35 per share. 351,750
10/29/2020 391   Award at $0 per share. 0
02/12/2020 5,000   Disposition at $205.23 per share. 1,026,150
02/12/2020 5,000   Derivative/Non-derivative trans. at $61.46 per share. 307,300
10/24/2019 495   Award at $0 per share. 0
06/04/2019 5,000   Disposition at $203.67 per share. 1,018,350
06/04/2019 5,000   Derivative/Non-derivative trans. at $63.03 per share. 315,150
10/25/2018 514   Award at $0 per share. 0
08/23/2018 10,000   Disposition at $187.92 per share. 1,879,200
08/23/2018 10,000   Derivative/Non-derivative trans. at $61.08 per share. 610,800
10/26/2017 739   Award at $0 per share. 0
10/27/2016 914   Award at $0 per share. 0
09/08/2016 1,700   Disposition at $109.83 per share. 186,711

Officers and Executives

Mr. Charles R. Kummeth
President, Chief Executive Officer & Director
Mr. James T. Hippel
CFO & Principal Accounting Officer
Dr. Robert Monroe
Chief Medical Officer
Mr. Kim Kelderman
President-Diagnostics & Genomics
Ms. Brenda Swierenga Furlow
Secretary, Senior Vice President & General Counsel
Mr. Robert M. Gavin
Senior Vice President-Analytical Systems Division
Mr. Kevin S. Gould
Senior Vice President-Diagnostics Division
Mr. David Clair
Senior Director-Investor Relations
Mr. Struan Robertson
Vice President–Human Resources
Mr. Robert V. Baumgartner
Chairman
Dr. Rupert J. Vessey
Independent Director
Ms. Julie L. Bushman
Independent Director
Dr. Randolph C. Steer
Independent Director
Mr. John L. Higgins
Independent Director
Dr. Roeland Nusse
Independent Director
Dr. Alpna H. Seth
Independent Director
Dr. Joseph D. Keegan
Independent Director
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.